1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Social Anxiety Disorders (SAD) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Social Anxiety Disorders (SAD)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Social Anxiety Disorders (SAD).
- A review of the marketed products under prescription for Social Anxiety Disorders (SAD), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Social Anxiety Disorders (SAD) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Social Anxiety Disorders (SAD) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Social Anxiety Disorders (SAD) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Social Anxiety Disorders (SAD) drugs.
- Coverage of Social Anxiety Disorders (SAD) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Social Anxiety Disorders (SAD) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Social Anxiety Disorders (SAD).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Social Anxiety Disorders (SAD).
- API intelligence over marketed drugs for Social Anxiety Disorders (SAD) and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Social Anxiety Disorders (SAD).
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Social Anxiety Disorders (SAD) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Social Anxiety Disorders (SAD) Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Social Anxiety Disorders (SAD) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Social Anxiety Disorders (SAD) Therapeutic Market, US, (Year), 2014
Social Anxiety Disorders (SAD) Marketed Drugs, API Manufacturers by US DMF Status, 2014
Social Anxiety Disorders (SAD) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Social Anxiety Disorders (SAD) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Social Anxiety Disorders (SAD) Therapeutic Market, Global Sales (in million USD), 2014
Social Anxiety Disorders (SAD) Marketed Drugs, API Manufacturers, Global, 2014
Social Anxiety Disorders (SAD) Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Social Anxiety Disorders (SAD), 2014?


List of Figures

Social Anxiety Disorders (SAD) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Social Anxiety Disorders (SAD) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Social Anxiety Disorders (SAD) Therapeutic Market, US, (Year), 2014
Social Anxiety Disorders (SAD) Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Social Anxiety Disorders (SAD) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Social Anxiety Disorders (SAD) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Social Anxiety Disorders (SAD) Therapeutic Market, Global Sales (in million USD), 2014
Social Anxiety Disorders (SAD) Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Agoraphobia Global Clinical Trials Review, H2, 2016

Agoraphobia Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Agoraphobia Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Agoraphobia Global Clinical Trials Review, H2, 2016" provides an overview of Agoraphobia clinical trials ...

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2016

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • September 2016
  • by Global Data

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2016" ...

Anxiety Disorders-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Anxiety Disorders-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Anxiety Disorders-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.